Seqera Labs Secures $5.5M Funding for COVID-19 Variant Sequencing

Unlocking Insights from Complex Life Science Data

The ability to organize and interpret unstructured information from various sources represents a major advancement in the big data landscape. A European startup is addressing this challenge specifically within the life sciences, and has notably assisted labs in identifying two significant COVID-19 variants.

Seqera Labs Secures Seed Funding

Seqera Labs, based in Barcelona, has secured $5.5 million in seed funding to expand its data orchestration and workflow platform. This platform is designed to help scientists and engineers extract meaningful insights from cloud-based genomic data and other complex life science applications.

Investment Details

Talis Capital and Speedinvest co-led the funding round. Participation also came from BoxOne Ventures, a previous investor, and a grant from the Chan Zuckerberg Initiative, which supports open-source software for scientific endeavors.

Early Traction and Revenue Generation

Seqera, a combination of “sequence” and “era,” previously raised under $1 million. The company is already generating revenue, with five of the world’s largest pharmaceutical companies among its clientele, alongside biotech and other life science organizations.

Origins at the Centre for Genomic Regulation

Seqera originated from the Centre for Genomic Regulation in Barcelona. It was developed as the commercial application of Nextflow, an open-source workflow and data orchestration software created by Seqera’s founders, Evan Floden and Paolo Di Tommaso.

The Genesis of Seqera

Evan Floden, Seqera’s CEO, explained that the company was founded in 2018 after Nextflow gained significant adoption within the life science community. This led to repeated requests for customization and additional features.

Usage Statistics

Both Nextflow and Seqera have experienced substantial usage. The Nextflow runtime has been downloaded over 2 million times, and Seqera’s cloud offering has processed more than 5 billion tasks.

COVID-19 Pandemic as a Catalyst

The COVID-19 pandemic highlighted the critical need for Seqera’s capabilities. Millions of genetic samples collected from COVID-19 tests represent a valuable resource for understanding the virus’s mutations and spread.

Addressing Data Silos

The challenge isn’t a lack of data, but rather the difficulty of analyzing it holistically. Data resides in numerous locations, is constantly growing, and changing, making traditional data centralization approaches inefficient and costly.

Seqera’s Unique Approach

Seqera’s technology treats each data source as a pipeline that can be merged and analyzed as a unified entity, without moving the data from its original infrastructure. This allows scientists to query the information for deeper insights.

Key Role in Variant Discovery

Seqera played a central role in identifying both the Alpha and Delta variants of the COVID-19 virus, and continues to contribute to ongoing research.

Expanding into Precision Medicine

Seqera is also being applied to other medical fields, such as precision medicine. This approach is particularly promising in oncology, where cancer’s behavior varies based on individual genetic factors.

Personalized Treatment Through Data Analysis

Leveraging machine learning and big data analytics, researchers are striving to understand individual cancers and develop more personalized treatments. Seqera facilitates the sequencing of this crucial data.

Empowering Researchers with a User-Friendly Platform

The Seqera platform is designed for direct use by researchers and scientists, minimizing the need for specialized data expertise. This aligns with the growing trend of “no-code/low-code” software, making complex processes accessible to a wider audience.

Investment Rationale

The company’s existing opportunities and potential applications across various cloud-based data types make it an attractive investment.

Investor Perspectives

Kirill Tasilov, principal at Talis Capital, stated that advancements in machine learning and data proliferation are increasing the cost of life science experiments. He emphasized Nextflow’s widespread adoption and Seqera’s role in modernizing the industry.

Arnaud Bakker, principal at Speedinvest, added that the increasing volume and complexity of biological data necessitate advanced tooling. He highlighted Seqera’s open and cloud-first framework for scaling data analysis and enabling data-driven solutions.

Beyond Life Sciences

While medicine and life sciences are current focal points, Seqera’s framework can be applied to other areas, including AI training, image analysis, and astronomy.

Looking Ahead

Evan Floden believes that biology is the defining scientific field of the 21st century, becoming increasingly data-centric. Seqera aims to provide the services needed to support this evolution.